Literature DB >> 24677373

Molecular mechanisms of bone metastasis and associated muscle weakness.

David L Waning1, Theresa A Guise2.   

Abstract

Bone is a preferred site for breast cancer metastasis and leads to pathologic bone loss due to increased osteoclast-induced bone resorption. The homing of tumor cells to the bone depends on the support of the bone microenvironment in which the tumor cells prime the premetastatic niche. The colonization and growth of tumor cells then depend on adaptations in the invading tumor cells to take advantage of normal physiologic responses by mimicking bone marrow cells. This concerted effort by tumor cells leads to uncoupled bone remodeling in which the balance of osteoclast-driven bone resorption and osteoblast-driven bone deposition is lost. Breast cancer bone metastases often lead to osteolytic lesions due to hyperactive bone resorption. Release of growth factors from bone matrix during resorption then feeds a "vicious cycle" of bone destruction leading to many skeletal-related events. In addition to activity in bone, some of the factors released during bone resorption are also known to be involved in skeletal muscle regeneration and contraction. In this review, we discuss the mechanisms that lead to osteolytic breast cancer bone metastases and the potential for cancer-induced bone-muscle cross-talk leading to skeletal muscle weakness. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 24677373      PMCID: PMC4058425          DOI: 10.1158/1078-0432.CCR-13-1590

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  72 in total

1.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Authors:  P I Croucher; C M Shipman; J Lippitt; M Perry; K Asosingh; A Hijzen; A C Brabbs; E J van Beek; I Holen; T M Skerry; C R Dunstan; G R Russell; B Van Camp; K Vanderkerken
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

2.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.

Authors:  Xin Lu; Euphemia Mu; Yong Wei; Sabine Riethdorf; Qifeng Yang; Min Yuan; Jun Yan; Yuling Hua; Benjamin J Tiede; Xuemin Lu; Bruce G Haffty; Klaus Pantel; Joan Massagué; Yibin Kang
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

3.  Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Emidio E Pistilli; Sasha Bogdanovich; Marcus D Goncalves; Rexford S Ahima; Jennifer Lachey; Jasbir Seehra; Tejvir Khurana
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 4.  Involvement of activin in the regulation of bone metabolism.

Authors:  R Sakai; Y Eto
Journal:  Mol Cell Endocrinol       Date:  2001-06-30       Impact factor: 4.102

5.  The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion.

Authors:  Jitesh Pratap; Amjad Javed; Lucia R Languino; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

6.  ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.

Authors:  Xin Lu; Qiongqing Wang; Guohong Hu; Catherine Van Poznak; Martin Fleisher; Michael Reiss; Joan Massagué; Yibin Kang
Journal:  Genes Dev       Date:  2009-07-16       Impact factor: 11.361

7.  Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion.

Authors:  Abdullah Karadag; Kalu U E Ogbureke; Neal S Fedarko; Larry W Fisher
Journal:  J Natl Cancer Inst       Date:  2004-06-16       Impact factor: 13.506

8.  Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.

Authors:  Toru Hiraga; Shinae Kizaka-Kondoh; Kiichi Hirota; Masahiro Hiraoka; Toshiyuki Yoneda
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

Review 9.  Bone metastasis: pathogenesis and therapeutic implications.

Authors:  Philippe Clezardin; Anna Teti
Journal:  Clin Exp Metastasis       Date:  2007-11-16       Impact factor: 5.150

10.  Estimation of Cachexia among Cancer Patients Based on Four Definitions.

Authors:  Kathleen M Fox; John M Brooks; Shravanthi R Gandra; Richard Markus; Chiun-Fang Chiou
Journal:  J Oncol       Date:  2009-07-01       Impact factor: 4.375

View more
  41 in total

1.  Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.

Authors:  Eric Hesse; Saskia Schröder; Diana Brandt; Jenny Pamperin; Hiroaki Saito; Hanna Taipaleenmäki
Journal:  JCI Insight       Date:  2019-04-09

Review 2.  Molecular alterations that drive breast cancer metastasis to bone.

Authors:  Penelope D Ottewell; Liam O'Donnell; Ingunn Holen
Journal:  Bonekey Rep       Date:  2015-03-18

Review 3.  Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity.

Authors:  Gabriel M Pagnotti; Maya Styner; Gunes Uzer; Vihitaben S Patel; Laura E Wright; Kirsten K Ness; Theresa A Guise; Janet Rubin; Clinton T Rubin
Journal:  Nat Rev Endocrinol       Date:  2019-06       Impact factor: 43.330

Review 4.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

Review 5.  Cancer-associated muscle weakness: What's bone got to do with it?

Authors:  David L Waning; Theresa A Guise
Journal:  Bonekey Rep       Date:  2015-05-20

6.  Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.

Authors:  Yuefeng Yang; Weidong Xu; Thomas Neill; Zebin Hu; Chi-Hsiung Wang; Xianghui Xiao; Stuart R Stock; Theresa Guise; Chae-Ok Yun; Charles B Brendler; Renato V Iozzo; Prem Seth
Journal:  Hum Gene Ther       Date:  2015-11-10       Impact factor: 5.695

Review 7.  The Role of TGFβ in Bone-Muscle Crosstalk.

Authors:  Jenna N Regan; Trupti Trivedi; Theresa A Guise; David L Waning
Journal:  Curr Osteoporos Rep       Date:  2017-02       Impact factor: 5.096

Review 8.  Hypoxia: Signaling the Metastatic Cascade.

Authors:  Erinn B Rankin; Jin-Min Nam; Amato J Giaccia
Journal:  Trends Cancer       Date:  2016-06-02

Review 9.  MicroRNAs in Bone Metastasis.

Authors:  Eric Hesse; Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2019-06       Impact factor: 5.096

10.  Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.

Authors:  Adrienne Boire; Yilong Zou; Jason Shieh; Danilo G Macalinao; Elena Pentsova; Joan Massagué
Journal:  Cell       Date:  2017-03-09       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.